You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

TOBRAMYCIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tobramycin patents expire, and when can generic versions of Tobramycin launch?

Tobramycin is a drug marketed by Alcon Pharms Ltd, Alembic, Apotex Inc, Bausch And Lomb, Chartwell Rx, Gland Pharma Ltd, Somerset Theraps Llc, Alkem Labs Ltd, Amneal Pharms, Dr Reddys Labs Sa, Hikma, Luoxin Aurovitas, Lupin, Mankind Pharma, Micro Labs, Mylan, Sun Pharm, Teva Pharms Usa, Amneal, Padagis Us, Apothecon, Baxter Hlthcare Corp, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Mylan Labs Ltd, Slate Run Pharma, Watson Labs Inc, Xellia Pharms Aps, and Xgen Pharms. and is included in fifty-five NDAs.

The generic ingredient in TOBRAMYCIN is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tobramycin

A generic version of TOBRAMYCIN was approved as tobramycin sulfate by HIKMA on April 26th, 1991.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TOBRAMYCIN?
  • What are the global sales for TOBRAMYCIN?
  • What is Average Wholesale Price for TOBRAMYCIN?
Drug patent expirations by year for TOBRAMYCIN
Drug Prices for TOBRAMYCIN

See drug prices for TOBRAMYCIN

Drug Sales Revenue Trends for TOBRAMYCIN

See drug sales revenues for TOBRAMYCIN

Recent Clinical Trials for TOBRAMYCIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Clarametyx Biosciences, Inc.Phase 1/Phase 2
Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 4
University of UtahEarly Phase 1

See all TOBRAMYCIN clinical trials

Pharmacology for TOBRAMYCIN
Medical Subject Heading (MeSH) Categories for TOBRAMYCIN
Paragraph IV (Patent) Challenges for TOBRAMYCIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BETHKIS Inhalation Solution tobramycin 300 mg/4 mL 201820 1 2017-08-31
TOBI Inhalation Solution tobramycin 300 mg/5 mL 050753 1 2009-06-29

US Patents and Regulatory Information for TOBRAMYCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira TOBRAMYCIN SULFATE tobramycin sulfate INJECTABLE;INJECTION 063080-001 Apr 30, 1991 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa TOBRAMYCIN SULFATE tobramycin sulfate INJECTABLE;INJECTION 065122-002 Nov 29, 2002 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan Labs Ltd TOBRAMYCIN SULFATE tobramycin sulfate INJECTABLE;INJECTION 065407-001 Mar 11, 2008 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hospira TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER tobramycin sulfate INJECTABLE;INJECTION 063081-006 Jun 2, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Igi Labs Inc TOBRAMYCIN SULFATE tobramycin sulfate INJECTABLE;INJECTION 063119-001 Oct 31, 1994 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for TOBRAMYCIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Viatris Healthcare Limited Tobi Podhaler tobramycin EMEA/H/C/002155
Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorised no no no 2011-07-20
Pari Pharma GmbH Vantobra (previously Tobramycin PARI) tobramycin EMEA/H/C/005086
Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorised no no no 2019-02-18
Pari Pharma GmbH Vantobra tobramycin EMEA/H/C/002633
Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Withdrawn no no no 2015-03-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.